Clinical trials: Monoclonal
HIV
PRO 140 for Human Immunodeficiency Virus
PRO 140 2102 is a multicenter, randomized, double-blind, placebo-controlled, clinical trial of observed systemic, long-acting, anti-HIV treatment with a monoclonal CCR5 antibody (PRO 140) as an adjunct to a new, optimized, oral…
- Trial name
- NCT02438345
- Testing
- PRO 140
- Where
- United States
- Sponsor
- Drexel University
Esophageal Squamous Cell Carcinoma
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
To evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and platinum chemotherapy in the preoperative treatment of locally advanced thoracic esophageal squamous cell carcinoma
- Trial name
- NCT04767295
- Testing
- Camrelizumab, Albumin Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Hunan Cancer Hospital
Non-Squamous Non-Small Cell Lung Cancer
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
This is a randomized, open-label, multicenter, phase 2 study comparing Paclitaxel/Carboplatin with or without bavituximab in patients that have previously untreated locally advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT01160601
- Testing
- Paclitaxel / Carboplatin, bavituximab
- Where
- 40 sites in United States, Georgia and 3 more
- Volunteers
- 86 people
- Sponsor
- Peregrine Pharmaceuticals
Sarcoma, Synovial
First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10
Advanced synovial sarcoma represents an unmet medical need. The gene encoding frizzled homologue 10 (FZD10), a 7-transmenbrane receptor, member of the Wnt signalling receptor family, is overexpressed in SS and is undetectable in…
- Trial name
- SYNFRIZZ (NCT01469975)
- Testing
- OTSA101-DTPA-90Y level 1, OTSA101-DTPA-90Y level 2, OTSA101-DTPA-90Y level 3
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Leon Berard
Colorectal Cancer, Locally Advanced
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain.
- Conditions
- Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT00819169
- Testing
- AMG 479, AMG 655
- Volunteers
- 89 people
- Sponsor
- NantCell, Inc.
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-INCLINE (NCT07430956)
- Testing
- REGN7508, REGN9933
- Where
- 44 sites in United States, Canada
- Volunteers
- 2,628 people
- Sponsor
- Regeneron Pharmaceuticals
Small Cell Carcinoma of Esophagus, Advanced Cancer
Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy
To evaluate the anti-tumor activity, safety and tolerance of toripalimab as monotherapy for patients with small cell esophageal cancer (SCCE), and to explore the potential biomarkers for this treatment.
- Trial name
- NCT03811379
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Asthma
Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers
Phase I study to evaluate the safety and tolerability of escalating single IV doses of MEDI-528.
- Trial name
- NCT00192296
- Testing
- MEDI-528 0.3 mg/kg, MEDI-528 1 mg/kg, MEDI-528 3 mg/kg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Dermatitis, Atopic
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
- Trial name
- NCT07540442
- Testing
- MG-K10 Injection (Humanized Monoclonal Antibody)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Carcinoma, Non-Squamous Non-Small-Cell Lung Cancer
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
A 2-part study to examine safety, tolerability and pharmacokinetics (part 1), and anti-tumour effects (part 2), of CDP791 combined with carboplatin and paclitaxel.
- Trial name
- NCT00152477
- Testing
- Carboplatin, Paclitaxel, CDP791 10mg/kg
- Where
- 21 sites in Hungary, Poland and 1 more
- Volunteers
- 165 people
- Sponsor
- UCB Pharma
Multiple Sclerosis
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
Primary Objective: To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions Secondary Objective: To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI…
- Trial name
- NCT04879628
- Testing
- SAR441344 IV, SAR441344 SC, MRI contrast-enhancing preparations
- Where
- 37 sites in United States, Bulgaria and 8 more
- Volunteers
- 129 people
- Sponsor
- Sanofi
Arthritis, Osteoarthritis
Tanezumab In Osteoarthritis Of The Knee (2)
The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis.
- Trial name
- NCT00830063
- Testing
- tanezumab 10 mg, tanezumab 5 mg, naproxen
- Where
- 94 sites in United States
- Volunteers
- 832 people
- Sponsor
- Pfizer
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
This phase I/II trial studies the side effects and the best dose of radiolabeled monoclonal antibody when given together with combination chemotherapy before stem cell transplant and to see how well it works in treating patients…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01921387
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Haematological Malignancy, Colorectal Neoplasms
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other…
- Conditions
- Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms
- Trial name
- DETERMINE (NCT05786716)
- Testing
- Trastuzumab, Pertuzumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Lymphoma
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies such as yttrium Y90 ibritumomab tiuxetan can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00058292
- Testing
- filgrastim, rituximab, Carmustine
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
Advanced Biliary Tract Cancer
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
This study is a clinical study to explore the efficacy and safety of BL-B01D1+PD-1/PD-L1 monoclonal antibody in patients with advanced biliary tract cancer.
- Trial name
- NCT06978114
- Testing
- BL-B01D1, Pembrolizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
End-Stage Kidney Disease (ESKD)
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
This study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard…
- Trial name
- NCT07759167
- Testing
- REGN9933, REGN7508, REGN9533
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
SARS-CoV-2
AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics
This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD7442 administered intramuscularly (IM) or intravenously (IV) in pediatric participants aged ≥ 29 weeks GA to < 18 years.
- Trial name
- TRUST (NCT05281601)
- Testing
- AZD7442
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Cancer, Neoplasm Metastasis
Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
- Trial name
- NCT00492830
- Testing
- TRC093 recombinant humanized IgG1k monoclonal antibody
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Tracon Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.